

Howard S Hochster

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7129955/publications.pdf>

Version: 2024-02-01

82
papers

4,690
citations

361413

20
h-index

102487

66
g-index

82
all docs

82
docs citations

82
times ranked

6835
citing authors

#	ARTICLE	IF	CITATIONS
1	Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. <i>Journal of Geriatric Oncology</i> , 2022, 13, 469-479.	1.0	3
2	Bias and Pancreatic Cancer Reporting. <i>Journal of the National Cancer Institute</i> , 2022, 114, 641-642.	6.3	2
3	Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. <i>Blood</i> , 2022, 139, 1684-1693.	1.4	56
4	Making Fluorouracil "Sexy" Again. <i>Journal of the National Cancer Institute</i> , 2021, 113, 351-352.	6.3	1
5	Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma. <i>JAMA Oncology</i> , 2021, 7, 421.	7.1	159
6	Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. <i>Blood Advances</i> , 2021, 5, 1737-1745.	5.2	4
7	Preoperative pembrolizumab for MSI high, EBV positive or PD-L1 positive locally advanced gastric cancer followed by surgery and adjuvant chemoradiation with pembrolizumab: Interim results of a phase 2 multi-center trial (NCT03257163).. <i>Journal of Clinical Oncology</i> , 2021, 39, e16111-e16111.	1.6	4
8	Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. <i>Clinical Cancer Research</i> , 2021, 27, 6314-6322.	7.0	22
9	A phase 1b expansion study of TAS102 with oxaliplatin for refractory metastatic colorectal cancer. <i>Cancer</i> , 2021, 127, 1417-1424.	4.1	5
10	Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2557-2566.	1.4	1
11	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa024.	2.9	8
12	Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. <i>JAMA Network Open</i> , 2020, 3, e2023500.	5.9	8
13	Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4814-4822.	7.0	82
14	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	27.6	218
15	Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22a05): a single-arm, phase 1b/2 trial. <i>Lancet Oncology</i> , 2020, 21, 1066-1076.	10.7	130
16	Young-Onset Colon Cancer and Recurrence Risk by Gene Expression. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1170-1173.	6.3	6
17	Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 1555-1562.	7.0	10
18	The Evolving Role of Radiotherapy in Locally Advanced Rectal Cancer and the Potential for Nonoperative Management. <i>Oncology & Hematology Review</i> , 2020, 16, 43-51.	0.2	1

#	ARTICLE	IF	CITATIONS
19	Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes. <i>Frontiers in Oncology</i> , 2019, 9, 345.	2.8	10
20	Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up. <i>Oncologist</i> , 2019, 24, 1039-e642.	3.7	16
21	Tools from the World of Artificial Intelligence in Interventional Oncology: Be Careful What You Wish For. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 339-341.	0.5	5
22	The role of comprehensive molecular profiling in colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2019, 17, 663-665.	0.3	0
23	NCCN Guidelines Insights: Colon Cancer, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 359-369.	4.9	675
24	A 71-year-old man with a hemorrhagic vesicular eruption. <i>International Journal of Dermatology</i> , 2018, 57, 147-148.	1.0	3
25	Identification of a Genomic Region between <i>SLC29A1</i> and <i>HSP90AB1</i> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2018, 24, 4734-4744.	7.0	14
26	Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).. <i>Journal of Clinical Oncology</i> , 2018, 36, 140-140.	1.6	13
27	A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139).. <i>Journal of Clinical Oncology</i> , 2018, 36, 208-208.	1.6	19
28	Association of RAS mutations with race in metastatic colorectal cancer: CALGB/SWOG 80405 (ALLIANCE).. <i>Journal of Clinical Oncology</i> , 2018, 36, 638-638.	1.6	3
29	SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX versus gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS547-TPS547.	1.6	3
30	An open-label, phase II study of intravenous anetumab ravtansine, an anti-mesothelin antibody drug conjugate, in pretreated mesothelin-expressing advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS540-TPS540.	1.6	2
31	Trial in progress: A multicenter phase II study of pembrolizumab in patients with advanced small bowel adenocarcinomas.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS535-TPS535.	1.6	0
32	Age distribution of tumor gene expression in patients with stage II/III colon cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 552-552.	1.6	0
33	Safety of trifluridine/tipiracil (FTD/TPI) in elderly patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 752-752.	1.6	1
34	A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. <i>Oncologist</i> , 2017, 22, 264-271.	3.7	45
35	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2392.	7.4	670
36	Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylolation Inhibitor. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1041-1053.	4.1	12

#	ARTICLE	IF	CITATIONS
37	Randomized trial of irinotecan and cetuximab with or without vemurafenib in <i>BRAF</i> -mutant metastatic colorectal cancer (SWOG 1406).. <i>Journal of Clinical Oncology</i> , 2017, 35, 520-520.	1.6	100
38	A Long-Term Survivor of Metastatic Pancreatic Adenocarcinoma: Free of Recurrence 12 Years After Treatment of Oligometastatic Disease. <i>Cureus</i> , 2017, 9, e1007.	0.5	4
39	Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. <i>British Journal of Cancer</i> , 2016, 114, 737-743.	6.4	159
40	TAS-102: a novel antimetabolite for the 21st century. <i>Future Oncology</i> , 2016, 12, 153-163.	2.4	17
41	Impact of primary (1 st) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3504-3504.	1.6	249
42	Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced <i>BRAF</i> -mutant colorectal cancer (<i>BRAF</i> m CRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3544-3544.	1.6	79
43	Efficacy and safety results in patients with impaired renal and hepatic function in the RECURSE trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3547-3547.	1.6	3
44	Onset of neutropenia as an indicator of treatment response in the phase III RECURSE trial of TAS-102 vs placebo in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3556-3556.	1.6	5
45	Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3597-3597.	1.6	9
46	Supportive treatment for hematologic toxicities in the phase 3 RECURSE trial of TAS-102 vs placebo with best supportive care in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15021-e15021.	1.6	5
47	<i>nab</i> -paclitaxel (<i>nab</i> -P) + nivolumab (Nivo) ± gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS475-TPS475.	1.6	7
48	Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 395-395.	1.6	0
49	Association of chemotherapy induced neutropenia at 1-month mark (CIN-1-month) and overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A Cohort study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15124-e15124.	1.6	0
50	Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity. <i>Experimental Hematology and Oncology</i> , 2015, 4, 29.	5.0	49
51	Cancer Stem Cells: The Promise and the Potential. <i>Seminars in Oncology</i> , 2015, 42, S3-S17.	2.2	256
52	Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1909-1919.	27.0	1,027
53	S0713: A phase II study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX) and capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 3516-3516.	1.6	3
54	SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4004-4004.	1.6	26

#	ARTICLE	IF	CITATIONS
55	SWOG S1115: Randomized phase II trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in pretreated patients (Pts) with metastatic pancreatic cancer.. Journal of Clinical Oncology, 2015, 33, 4119-4119.	1.6	11
56	Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405.. Journal of Clinical Oncology, 2015, 33, 6504-6504.	1.6	9
57	Final analysis of a phase II study of Yale-modified FOLFIRINOX (mFOLFIRINOX) in metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology, 2015, 33, 395-395.	1.6	16
58	A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, 663-663.	1.6	4
59	Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, 704-704.	1.6	92
60	S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, TPS790-TPS790.	1.6	2
61	E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second line therapy of KRAS wild type colorectal cancer (CRC).. Journal of Clinical Oncology, 2015, 33, TPS793-TPS793.	1.6	1
62	The Yale Gastrointestinal Cancer Biorepository: A comprehensive biospecimen and data resource for studying determinants of pancreatic ductal adenocarcinoma prognosis following curative-intent pancreaticoduodenectomy.. Journal of Clinical Oncology, 2015, 33, 272-272.	1.6	35
63	SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer.. Journal of Clinical Oncology, 2015, 33, TPS4142-TPS4142.	1.6	0
64	Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405.. Journal of Clinical Oncology, 2015, 33, 3585-3585.	1.6	0
65	Phase II study of Yale modified FOLFIRINOX (mFOLFIRINOX) in locally advanced pancreatic cancer (LAPC).. Journal of Clinical Oncology, 2015, 33, e15274-e15274.	1.6	0
66	Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology, 2014, 32, e15226-e15226.	1.6	5
67	CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).. Journal of Clinical Oncology, 2014, 32, 1BA3-1BA3.	1.6	68
68	E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC).. Journal of Clinical Oncology, 2014, 32, TPS3665-TPS3665.	1.6	1
69	CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).. Journal of Clinical Oncology, 2014, 32, 1BA3-1BA3.	1.6	178
70	Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology, 2014, 32, 256-256.	1.6	4
71	Second-line gemcitabine plus nab-paclitaxel (G+A) for advanced pancreatic cancer (APC) after first-line FOLFIRINOX: Single institution retrospective review of efficacy and toxicity.. Journal of Clinical Oncology, 2014, 32, 344-344.	1.6	2
72	Measurement of circulating tumor DNA as a cancer biomarker in gastrointestinal malignancies using a novel next-generation sequencing method.. Journal of Clinical Oncology, 2014, 32, 217-217.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors.. Journal of Clinical Oncology, 2014, 32, 2561-2561.	1.6	0
74	Monitoring changes in circulating tumor DNA in gastrointestinal malignancies using a novel next-generation sequencing method.. Journal of Clinical Oncology, 2014, 32, 3645-3645.	1.6	0
75	The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience. Blood, 2013, 122, 3060-3060.	1.4	5
76	The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC).. Journal of Clinical Oncology, 2013, 31, 3587-3587.	1.6	1
77	Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study.. Journal of Clinical Oncology, 2013, 31, 4011-4011.	1.6	20
78	Phase II study of mFOLFOX with bevacizumab (Bev) in metastatic gastroesophageal and gastric (GE) adenocarcinoma (AC).. Journal of Clinical Oncology, 2013, 31, 4084-4084.	1.6	1
79	Second-line therapy of KRAS-mutated (KRASm) metastatic colorectal cancer (CRC) with the MEK inhibitor selumetinib ([SEL], AZ6244, ARRY-142886) in combination with irinotecan (IRI): An AGICC study.. Journal of Clinical Oncology, 2013, 31, 380-380.	1.6	4
80	A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study.. Journal of Clinical Oncology, 2013, 31, 67-67.	1.6	12
81	Single-institution experience with FOLFIRINOX in advanced pancreatic cancer (PC).. Journal of Clinical Oncology, 2012, 30, 330-330.	1.6	6
82	Single institution experience with FOLFIRINOX in advanced pancreatic cancer (PC).. Journal of Clinical Oncology, 2012, 30, e14534-e14534.	1.6	4